Navigation Links
GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
Date:3/26/2013

OXFORD, England, March 26, 2013 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, will present the results of its cardiac surgery intensive care trial and plans for CE mark testing at two leading MedTech conferences this spring. GlySure CEO Christopher Jones will speak at the inaugural Biovision Investor Conference on March 26th, 2013 in Lyon, France, and at the Investment In Innovation (IN³) Medical Device 360° Conference on April 17th, 2013 in Dublin, Ireland.

Studies have shown that inadequate post-operative blood sugar control in heart surgery patients is associated with an increased risk of major complications and death. GlySure recently completed a trial of its CBGM system on cardiac surgery patients.  The study revealed GlySure's technology can be used to continuously measure glucose levels with an extremely high degree of accuracy and repeatability across two-to-five days of a patient's stay in ICU, which is key to effectively implementing TGC.

At the Biovision Investor Conference and IN³ Medical Device 360° Conference, Jones will share results of GlySure's cardiac surgery ICU trial and outline the company's plans for CE regulatory trials, which are set to commence this Spring.

Biovision has selected GlySure as one of 35 life science companies to present to its forum of international capital investors and large healthcare companies seeking partnerships and innovation, while the producers of the (IN³) Medical Device 360° Conference have chosen GlySure as one of 35 early stage companies to appear before its global audience of VCs, top investors and corporate acquirers.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors, which can provide continuous glucose readings throughout the length of a patient's stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Media Contact: Kara Della Vecchia , KDV Communications, Inc. Tel: +1-508-314-3127. kara@kdvcommunications.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GlySure Earns ISO 13485 Certification
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
8. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
9. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
10. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
11. Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
Breaking Medicine News(10 mins):